`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`AMENDMENTSTO THE CLAIMS
`
`This listing of claims will replace all prior versions andlistings of claims in the
`
`application:
`
`Listing of Claims:
`
`Claims 1-14 (Cancelled).
`
`15.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine, or a therapeutically
`
`active salt thereof,
`
`in an oral dosage of 2.5 mg or 5 mg, and (} metformin
`
`wherein the dose of metformin is 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a
`
`day), or 300 mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose
`
`of 500 mg to 1000 mg onceortwice a day, or 500 mg to 2000 mg once a day,
`or
`
`wherein the dose of metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total
`
`daily dose of metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg
`
`metformin in delayed release form,
`or
`
`wherein the dose of metformin is 500 mg to 1000 mg.
`
`16.
`
`(Cancelled)
`
`17.
`
`(Previously presented) The method according to claim 15, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine and metformin are administered orally in the form of a fixed combination.
`
`18.
`
`(Previously presented) The method according to claim 17, wherein the fixed
`
`combinationis a tablet or capsule.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`19.
`
`(Previously presented) The method according to claim 17, wherein the fixed
`
`combination is a tablet.
`
`Claims 20-23.
`
`(Cancelled)
`
`24.
`
`(Previously presented) The method according to claim 17, wherein the dosage of
`
`1-[(4-methy]-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn- 1-yl)-8-(3-(R)-amino-
`
`piperidin-1-yl)-xanthine is 2.5 mg.
`
`25.
`
`(Previously presented) The method according to claim 17, wherein the dosage of
`
`1-[(4-methy]-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn- 1-yl)-8-(3-(R)-amino-
`
`piperidin-1-yl)-xanthine is 5 mg.
`
`26.
`
`(Cancelled)
`
`27.
`
`(Previously presented) The method according to claim 17, wherein metformin is
`
`provided in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 times a day), or 300 mg
`
`to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg to
`
`1000 mg once or twice a day, or 500 mg to 2000 mg once a day.
`
`28.
`
`(Currently amended) The method according to claim 17, wherein the dose of
`
`metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of
`
`metformin of 500[[-]} sus
`
`to 2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg
`
`
`metformin in delayed release form.
`
`29.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 500 mg to 1000 mg.
`
`30.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 500 mg.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`31.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 850 mg.
`
`32.
`
`(Previously presented) The method according to claim 17, wherein the amountof
`
`metformin is 1000 mg.
`
`33.
`
`(Cancelled)
`
`34,
`
`(Cancelled)
`
`35.
`
`(Previously presented) A method oftreating type 2 diabetes comprising
`
`administering twice daily to a patient in need thereof 1-[(4-methyl-quinazolin-2-
`
`yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in an oral
`
`dosage of 2.5 mg in fixed combination with metformin in an amount of 500 mg to 1000
`
`mg.
`
`36.
`
`(Currently amended) An oral tablet formulation comprising 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in an amountof 2.5 mg or 5 mg optionally in combination with metformin, and
`
`[[an]] a pharmaceutically acceptable carrier or diluent.
`
`37.
`
`(Previously presented) The oral tablet according to claim 36, containing 500 mg to
`
`1000 mg metformin.
`
`38.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`administering to a patient in need thereof {a} 1-[(4-methyl-quinazolin-2-yl)methyl]-3-
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and (3 metformin, i: the form of a fixed combination, wherein metforminis
`
`administered in a dose of 100 mg to 500 mg or 200 mg to 850 mg (1-3 timesa day), or 300
`
`mg to 1000 mg once or twice a day, or as delayed-release metformin in a dose of 500 mg
`
`to 1000 mg once or twice a day, or 500 mg to 2000 mg oncea day.
`
`
`
`U.S. Application No.: 14/161,007
`Response after Notice of Allowancedated July 27, 2015
`Attorney Docket No.: 01-2051-US-3
`
`39.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and (5) metformin, in the form of a fixed combination, wherein the dose of
`
`metformin is 500 mg, 850 mg or 1000 mg as a single dose with a total daily dose of
`
`metformin of 500-2850 mg, or 500 mg, 1000 mg, 1500 mg or 2000 mg metformin in
`
`delayed release form.
`
`40.
`
`(Currently amended) A methodoftreating type 2 diabetes comprising
`
`administering to a patient in need thereof {a} 1-[(4-methyl-quinazolin-2-yl)methyl]-3-
`
`methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine in a daily oral amountof
`
`5 mg and {}} metformin, in the form of a fixed combination, wherein the amountof
`
`metformin is 500 mg to 1000 mg.
`
`Al.
`
`(Previously presented) The method according to claim 15, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine is administered in a daily oral amountof 5 mg.
`
`42.
`
`(Previously presented) A method oftreating type 2 diabetes comprising
`
`administering to a patient in need thereofthe oral tablet of claim 36, wherein the daily oral
`
`amount of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-
`
`amino-piperidin-1-yl)-xanthine administered to said patient is 5 mg.
`
`43.
`
`(Previously presented) The method according to claim 24, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in a dosage of 2.5 mg is administered twice daily.
`
`44.
`
`(Previously presented) The method according to claim 25, wherein 1-[(4-methyl-
`
`quinazolin-2-yl)methy]]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin- 1-yl)-
`
`xanthine in a dosage of Smg is administered once daily.
`
`